Helix BioPharma Corp. (HBP.TO)
CAD 1.0
(5.26%)
CAD 1.0
(5.26%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -0.21 CAD | -28.83% |
| 2023 | -0.16 CAD | 19.9% |
| 2022 | -0.20 CAD | 29.09% |
| 2021 | -0.29 CAD | 18.58% |
| 2020 | -0.35 CAD | 0.14% |
| 2019 | -0.35 CAD | 18.48% |
| 2018 | -0.43 CAD | 21.27% |
| 2017 | -0.55 CAD | 0.0% |
| 2016 | -0.55 CAD | 0.0% |
| 2015 | -0.55 CAD | 8.33% |
| 2014 | -0.60 CAD | -412.82% |
| 2013 | -0.12 CAD | 91.0% |
| 2012 | -1.30 CAD | -52.94% |
| 2011 | -0.85 CAD | 29.17% |
| 2010 | -1.20 CAD | 11.11% |
| 2009 | -1.35 CAD | -68.75% |
| 2008 | -0.80 CAD | 27.27% |
| 2007 | -1.10 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -0.04 CAD | -100.0% |
| 2024 Q1 | -0.03 CAD | 45.37% |
| 2024 Q4 | -0.11 CAD | -155.81% |
| 2024 Q2 | -0.02 CAD | 27.12% |
| 2023 Q2 | -0.03 CAD | 35.48% |
| 2023 Q1 | -0.05 CAD | -22.37% |
| 2023 FY | - CAD | 19.9% |
| 2023 Q4 | -0.05 CAD | -61.19% |
| 2023 Q3 | -0.03 CAD | -11.67% |
| 2022 Q4 | -0.01 CAD | 13.64% |
| 2022 Q3 | -0.01 CAD | 36.23% |
| 2022 Q2 | -0.01 CAD | -15.97% |
| 2022 Q1 | -0.01 CAD | 36.02% |
| 2022 FY | - CAD | 29.09% |
| 2021 Q4 | -0.02 CAD | -2.76% |
| 2021 FY | - CAD | 18.58% |
| 2021 Q3 | -0.02 CAD | 1.09% |
| 2021 Q2 | -0.02 CAD | -976.47% |
| 2021 Q1 | -0.00 CAD | 89.44% |
| 2020 Q4 | -0.02 CAD | 16.15% |
| 2020 FY | - CAD | 0.14% |
| 2020 Q1 | -0.02 CAD | -12.27% |
| 2020 Q2 | -0.02 CAD | 2.73% |
| 2020 Q3 | -0.02 CAD | -7.87% |
| 2019 Q3 | -0.02 CAD | -1.56% |
| 2019 Q2 | -0.02 CAD | -43.28% |
| 2019 Q1 | -0.01 CAD | -8.06% |
| 2019 FY | - CAD | 18.48% |
| 2019 Q4 | -0.02 CAD | 16.41% |
| 2018 Q4 | -0.01 CAD | 42.06% |
| 2018 FY | - CAD | 21.27% |
| 2018 Q3 | -0.02 CAD | 16.41% |
| 2018 Q2 | -0.03 CAD | -7.56% |
| 2018 Q1 | -0.02 CAD | -150.53% |
| 2017 Q1 | -0.04 CAD | -85.5% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q4 | -0.01 CAD | 70.03% |
| 2017 Q3 | -0.03 CAD | -9.69% |
| 2017 Q2 | -0.03 CAD | 22.1% |
| 2016 Q1 | -0.03 CAD | -89.51% |
| 2016 Q2 | -0.03 CAD | 14.33% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q4 | -0.02 CAD | 24.53% |
| 2016 Q3 | -0.03 CAD | -0.76% |
| 2015 FY | - CAD | 8.33% |
| 2015 Q4 | -0.02 CAD | 30.77% |
| 2015 Q3 | -0.02 CAD | 33.33% |
| 2015 Q2 | -0.04 CAD | -25.36% |
| 2015 Q1 | -0.03 CAD | -101.44% |
| 2014 Q1 | -0.03 CAD | -116.33% |
| 2014 Q3 | -0.03 CAD | 19.89% |
| 2014 Q4 | -0.01 CAD | 52.72% |
| 2014 Q2 | -0.04 CAD | -15.41% |
| 2014 FY | - CAD | -412.82% |
| 2013 Q1 | -0.03 CAD | -167.24% |
| 2013 FY | - CAD | 91.0% |
| 2013 Q2 | 0.07 CAD | 325.81% |
| 2013 Q4 | -0.01 CAD | 55.72% |
| 2013 Q3 | -0.03 CAD | -147.43% |
| 2012 Q3 | -0.04 CAD | 69.14% |
| 2012 Q4 | -0.01 CAD | 73.15% |
| 2012 FY | - CAD | -52.94% |
| 2012 Q2 | -0.14 CAD | -191.67% |
| 2012 Q1 | -0.05 CAD | -144.9% |
| 2011 Q4 | -0.02 CAD | 54.42% |
| 2011 FY | - CAD | 29.17% |
| 2011 Q1 | -0.06 CAD | 0.0% |
| 2011 Q2 | -0.06 CAD | -9.46% |
| 2011 Q3 | -0.04 CAD | 29.85% |
| 2010 FY | - CAD | 11.11% |
| 2009 FY | - CAD | -68.75% |
| 2008 FY | - CAD | 27.27% |
| 2007 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Appili Therapeutics Inc. | -0.03 CAD | -573.077% |
| Eupraxia Pharmaceuticals Inc. | -1.58 CAD | 86.709% |
| Microbix Biosystems Inc. | -0.00 CAD | -69900.0% |
| Medicenna Therapeutics Corp. | -0.37 CAD | 43.243% |
| Satellos Bioscience Inc. | -0.18 CAD | -16.667% |
| Oncolytics Biotech Inc. | -0.41 CAD | 48.78% |
| Sernova Corp. | -0.13 CAD | -61.538% |